Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Inflectra Label Not Exactly Silent On Remicade's Orphan-Protected Claim

This article was originally published in The Pink Sheet Daily

Executive Summary

Although FDA did not approve the biosimilar for pediatric ulcerative colitis, Inflectra labeling states that a pediatric assessment demonstrates it is 'safe and effective in another pediatric indication.'


Related Content

Keytruda's New Tissue-Agnostic Indication Could Prompt Orphan Policy Changes
Amgen's Avastin Biosimilar May Revive Orphan Indication Concerns
Samsung’s Renflexis: Second US Biosimilar To Janssen’s Remicade, With A Few Firsts
Biosimilars: Postmarketing Data Alone Not Enough For Interchangeability
Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
Evolving Biosimilar Pathway Brings Mid-Review Policy Issues


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts